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Abstract
We report the first genome-wide association study of a joint analysis using 795 Han Chinese individuals with treatment-
refractory schizophrenia (TRS) and 806 controls. Three loci showed suggestive significant association with TRS were
identified. These loci include: rs10218843 (P=3.04610
27) and rs11265461 (P=1.94610
27) are adjacent to signaling
lymphocytic activation molecule family member 1 (SLAMF1); rs4699030 (P=1.94610
26) and rs230529 (P=1.74610
27) are
located in the gene nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1); and rs13049286
(P=3.05610
25) and rs3827219 (P=1.66610
25) fall in receptor-interacting serine/threonine-protein kinase 4 (RIPK4). One
isolated single nucleotide polymorphism (SNP), rs739617 (P=3.87610
25) was also identified to be associated with TRS. The
-94delATTG allele (rs28362691) located in the promoter region of NFKB1 was identified by resequencing and was found to
associate with TRS (P=4.85610
26). The promoter assay demonstrated that the -94delATTG allele had a significant lower
promoter activity than the -94insATTG allele in the SH-SY5Y cells. This study suggests that rs28362691 in NFKB1 might be
involved in the development of TRS.
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Introduction
Schizophrenia is a severe psychiatric disorder with a prevalence
estimated to be approximately 1% [1] in the world and 0.6% in
Taiwan [2]. It is the third-leading cause of disability among
individuals age between 15 and 44 [3]. Its clinical manifestations
are characterized by distortion of reality, delusions, hallucinations,
altered emotional reactivity, disorganized behavior, social isolation
and cognitive impairment. The etiology of schizophrenia is not
well understood but it has been postulated as a complex disease
with an estimated heritability as high as 80% [4] [5].
Genetic studies based on linkage and positional candidate genes
approaches have suggested multiple candidate molecules in the
pathogenesis of schizophrenia, including the receptors of antipsy-
chotics (DRD2 [6], HTR2A [7], CHRNA7 [8], TAAR6 [9]); the
enzymes affecting neurotransmitter metabolisms (COMT [10],
DAOA [11]), factors involved in microtubules function (DISC1
[12]), neuronal differentiation (NRG1 [13]), signal transduction
(RGS4 [14]) and calmodulin-dependent protein phosphatase
(PPP3CC [15]). However, most of these genes lack of replicable
support across populations [16,17].
Genome-wide association study (GWAS) is a hypothesis-free
approach to comprehensively identify disease susceptibility loci. It
has identified several susceptible genetic variants associated with
schizophrenia, such as SNPs located on or near genes involved in
transcriptional regulations (ZNF804A [18,19] and ZNF184 [20]);
neuronal functioning (NRGN [21], and ANK3 [22]); cytokine
activities (CSF2RA [23] and IL3RA [23]), inflammatory responses
(PLAA [22]), immune function (MHC region [20,21,24] and TCF4
[21]); brain development (RPGRIP1L [18], PLXNA2 [25], RELN
[26]); endocrine function (ACSM1 [22]); and chromatin remodel-
ing (SMARCA2 [27]). However, these studies have not replicated
the candidate genes or linkage studies in schizophrenia and most
of the findings from GWAS are still inconsistent. The discordant
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schizophrenia since schizophrenia is a heterogeneous disorder as
well as the lack of statistical power due to find common variants of
susceptibility.
Antipsychotic medication is the major treatment for schizo-
phrenia. However, one fifth to one third of schizophrenic patients
do not respond to antipsychotic treatments [28,29]. These patients
with treatment refractory schizophrenia (TRS) have persistent
psychotic symptoms combining with poor social/work function in
spite of administering at least two trials of sufficient antipsychotic
doses and adequate treatment duration [28]. Comparing with
those patients with adequate responses to antipsychotic treatments,
patients with TRS had significantly lower levels of catecholamine
in cerebrospinal fluid or plasma [30], increased cortical atrophy
[31,32], and a lower level of plasma tryptophan concentrations
[33]. Therefore, TRS may be a distinct and homogenous
subgroup of schizophrenia.
To identify the genetic variants susceptible for schizophrenia,
this study performed the first GWAS focusing on TRS in a Han-
Chinese population. We identified several novel genetic loci which
were not associated with schizophrenia. Our findings may pave a
new way to elucidate the underlying molecular mechanism of
schizophrenia and to improve the treatment for TRS.
Results
Demographic information
Demographic data from 522 TRS patients and 806 controls is
listed in Table 1. The mean age was 44.1269.06 years in cases
and 67.6469.36 years in controls. The male made up approxi-
mately 55% in cases and 48% in controls. Of these patients, 121
patients (23.2%) had a family history of psychiatric disorders; 264
patients (50.6%) displayed psychotic symptoms before age 20; 289
patients (55.4%) had shown violent or homicidal behavior; and
197 patients (37.7%) had attempted suicide. All of the patients
showed persistence of their illness for more than 5 years, with a
persistent CGI-S score of 4 or higher under antipsychotic
treatments.
Data quality
The average call rate was 99.860.3% for each subject
genotyped in this study. Gender determined from the GWAS
result for all the subjects were consistent with recorded data.
694,436 (79.99%) of the 868,114 SNP in the autosomes passed the
quality control filter and had an average call rate of 99.860.4%
(Supplementary Table S1). The results of principal component
analysis showed no significance for population stratification
between TRS patients and controls, (P.0.05, and Fst statistics
between populations ,0.001) (Supplementary Figure S1). Fur-
thermore, genomic control with a variance inflation factor
l=1.042 (trend test), estimated posterior to the regular GWAS,
also indicated no substantial population stratification. These SNPs
were then taken for further GWAS analysis.
Association analysis
Data analysis was first performed for the 522 TRS patients and
806 controls (Figure 1). Preliminary results revealed 19 SNPs with
suggestive significant associations with TRS (Supplementary Table
S2, 10
28,P,10
25). Fourteen markers were retained after cross
platform validation with the Sequenom platform and showed a
concordance rate of over 98% (Supplementary Table S2).
Four major clusters with more than one SNPs located within
500 kb of each other were identified from the 14 validated SNPs
(Table 2, Figure 2). The first locus, comprising rs10218843
(P=6.73610
26) and rs11265461 (P=5.90610
26), and is located
approximately 10 kb downstream of signaling lymphocytic activa-
tion molecule family member 1 (SLAMF1) on chromosome 1; the
second locus contains two SNPs, rs4699030 (P=8.41610
27)a n d
rs230529 (P=1.07610
26), is located in the introns of nuclear factor
of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1) on
chromosome 4; three SNPs, rs739617 (P=1.46610
25), rs17158926
(P=3.99610
25) and rs17158930 (P=3.08610
25) are clustered in
the introns of dedicator of cytokinesis 4 (DOCK4) on chromosome 7;
and the last locus which consists of two SNPs, rs13049286
(P=1.23610
25) and rs3827219 (P=1.23610
25), is located in
receptor-interacting serine/threonine-protein kinase 4 (RIPK4)o n
chromosome 21. These loci are located in the regions with high LD
(except for chromosome 21) (Supplementary Figure S2). Multi-
point/Haplotype analysis also showed that these clusters were
associated with TRS, the cluster on chromosome 4 had the highest
P value with global score P=2 610
25 (Supplementary Table S3).
In addition to the above SNPs in clusters, five other SNPs also
showed suggestive significant association with TRS. These SNPs
are: rs461409 (P=2.63610
26) which is located 175 kb down-
stream of RGM domain family, member B (RGMB)o n
chromosome 5; rs123533497 (P=1.04610
25) in intron 14 of A-
kinase anchor protein 9 (AKAP9) on chromosome 7; rs9314462
(P=5.30610
25) in the downstream of CUB and sushi domain-
containing protein 1 (CSMD1) on chromosome 8; rs9646303
(P=1.15610
25) in intron 3 of zinc finger, CCHC domain
containing 14 (ZCCHC14) on chromosome 16; and rs11673496
Table 1. Demographic and clinical characteristics for TRS.
Characteristics
Patients with
TRS (N=522)
Controls
(N=806)
Male (%) 289 (55.4%) 383 (47.5%)
Age- years 44.12 67.64
Body-mass index# 24.74 24.25
smoking - no. (%) 225 (43.1%) 270 (33.5%)
regular drinker - no. (%) 44 (8.4%) 90 (11.2%)
Family history of psychiatric disease 121 (23.2%) 33 (4.09%)
onset before 20 yr 264 (50.6%) -
violent or homicidal - no. (%) 289 (55.4%) -
suicide attempt - no. (%) 197 (37.7%) -
Recruitment for TRS - no. (%)
two trials of standard
antipsychotic treatments
90 (17.24) -
clozapine 432 (82.76) -
Severity of TRS : scale of CGI-S‘
1. normal 0 -
2. borderline mentally ill 0 -
3. mildly ill 0 -
4. moderately ill 129 (24.7%) -
5. markedly ill 265 (50.8%) -
6. severely ill 115 (22.0%) -
7. extremely ill 13 (2.5%) -
#means the body-mass index is the weight in kilograms divided by the square
of the height in meters.
‘means more than 5 years of persistence of illness without period of good social
or occupational functioning assayed by the severity of illness subscale of clinical
global impression (CGI-S).
doi:10.1371/journal.pone.0033598.t001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33598Figure 1. Graphical summary of genome-wide association analysis for TRS in a Han Chinese population. Results (2log10P) are shown in
chromosomal order for 694,436 SNPs which were tested in 522 cases and 806 controls by using Affymetrix SNP 6.0 Array. The horizontal line indicates
a P-value of 10
25.
doi:10.1371/journal.pone.0033598.g001
Table 2. Results of GWAS for TRS in Han population.
ch SNP position Allele RA
RAF in
control
RAF in
case
F
difference Ptrend OR (95% CI) Pjoint
ORjoint
(95% CI)
closest
gene
Distance
to gene
(bp)
1 rs10218843 158892685 CT C 0.407 0.495 0.088 6.73610
26 1.43 (1.22–1.67) 3.04610
27 1.45 (1.26–1.66) SLAMF1 8980
1 rs11265461 158896767 CT C 0.411 0.500 0.089 5.90610
26 1.43 (1.22–1.68) 1.94610
27 1.45 (1.26–1.67) SLAMF1 13062
4 rs230529 103676448 CT T 0.472 0.570 0.097 1.07610
26 1.48 (1.27–1.73) 1.74610
27 1.45 (1.26–1.66) NFKB1 0
4 rs4699030 103722862 CG C 0.470 0.568 0.098 8.41610
27 1.48 (1.27–1.73) 1.94610
26 1.40 (1.22–1.61) NFKB1 0
5 rs461409 97957866 AG G 0.793 0.864 0.071 2.63610
26 1.65 (1.33–2.05) 4.50610
24 1.39 (1.15–1.66) RGMB 2175034
7 rs12533497 91495608 CT T 0.071 0.122 0.051 1.04610
25 1.81 (1.39–2.36) 1.69610
24 1.60 (1.25–2.05) AKAP9 0
7 rs739617 111298102 AG A 0.130 0.191 0.061 1.46610
25 1.58 (1.28–1.95) 3.87610
25 1.50 (1.23–1.82) DOCK4 0
7 rs17158926 111298199 AT A 0.135 0.193 0.059 3.99610
25 1.54 (1.25–1.90) 5.08610
24 1.40 (1.16–1.70) DOCK4 0
7 rs17158930 111298374 AG G 0.134 0.193 0.059 3.08610
25 1.55 (1.26–1.91) 3.98610
24 1.41 (1.17–1.71) DOCK4 0
8 rs9314462 2501291 CT C 0.199 0.266 0.066 5.30610
25 1.45 (1.21–1.75) 5.35610
24 1.34 (1.13–1.59) CSMD1 2278992
16 rs9646303 86019470 CT C 0.409 0.496 0.087 1.15610
25 1.42 (1.22–1.67) 3.33610
24 1.30 (1.13–1.49) ZCCHC14 0
19 rs11673496 22581270 AG G 0.732 0.807 0.075 1.75610
25 1.53 (1.27–1.85) 2.24610
24 1.37 (1.16–1.61) ZNF492 260996
21 rs13049286 42049868 AC C 0.014 0.041 0.027 1.23610
25 3.08 (1.83–5.18) 3.05610
25 2.78 (1.70–4.56) RIPK4 0
21 rs3827219 42053555 AG A 0.014 0.042 0.028 1.23610
25 3.02 (1.81–5.03) 1.66610
25 2.80 (1.73–4.55) RIPK4 0
SNP position were indexed to the forward of NCBI Build 36.3.
ch: chromosome.
RA: Risk allele, the allele with higher frequency in schizophrenia as compared with controls;
RAF: risk allele frequency.
F: frequency.
Ptrend: P values obtained from the initial GWA analysis on 522 cases and 806 controls.
Pjoint: P values calculated from joint analysis on 804 cases and 806 controls.
OR, odds ratio for risk allele.
doi:10.1371/journal.pone.0033598.t002
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25), 60 kb upstream of zinc finger protein 492
(ZNF492) on chromosome 19 (Table 2, Supplementary Figure S3).
Except for rs13049286 and rs3827219 with odds ratio (OR) of
approximately 3, all other SNPs identified in this study showed
modest effects with OR between 1.06–1.81 (Table 2).
Joint Analysis in with additional TRS patients
The 14 SNPs showing suggestive significance were then genotyped
in an independent cohort of 273 TRS patients. An average call rate of
99.3760.21% was achieved for each subject. Joint analysis was then
carried out in the 795 cases and 806 controls. Of the 14 SNPs
showing suggestive association in the initial analysis, 7SNPs remain
suggestively associated with TRS after joint analysis (Table 2). These
SNPs are: rs10218843 (Pjoint=3.04 610
27) and rs11265461
(Pjoint=1.94610
27), which both are located in SLAMF1; rs230529
(Pjoint=1.47610
27) and rs4699030 (Pjoint=1.94 610
26) are located
in NFKB1; rs739617 (Pjoint=3.87 610
25) is in DOCK4; rs13049268
(Pjoint=3.05610
25) and rs3827219 (Pjoint=1.66 610
25)w h i c ha r e
located in RIPK4.
Testing in schizophrenic patients
The top SNPs showing suggestive significance were then tested
in an independent cohort of 1982 schizophrenic patients whose
responses to antipsychotic treatments were not determined and
additional 2000 controls. An average call rate of 99.3760.21%
was achieved for each subject. However, none of these SNPs were
significantly associated with this group of patients (Supplementary
Table S4), suggesting that these SNPs were specifically associated
with TRS and not a broad phenotype of schizophrenia.
Re-sequencing of NFKB1
Because the lowest P values in both single and multi-point
analysis were observed for the SNPs located on NFKB1 on
chromosome 4, we next aimed to identify variants with functional
consequence in NFKB1. Re-sequencing was performed on the
exons, intron-exon boundaries, and a 2-kb region covering the
promoter of NFKB1 in a discovery cohort of 94 TRS patients and
94 controls. Twenty-three genetic polymorphisms including 11
novel variants and 2 non-synonymous changes (R231L and
R534H) were identified in NFKB1 (Table 3). The rs28362491
SNP with an ATTG deletion in the promoter region of NFKB1
(94delATTG) was reported to affect nuclear protein binding and
gene transcription in colonic epithelial cells [34]. In a test with 520
TRS cases and 806 controls, rs28362491 was associated with TRS
(P=6.69610
25). rs28362491 is in linkage disequilibrium with
rs230529 and rs4699030 (r
2=0.741 and 0.714, respectively)
(Figure 3).
Functional analysis of rs28362491
Since rs28362491 has been reported to affect nuclear protein
binding and gene transcription in colonic epithelial cells, it is
possible that the deletion also alters the efficiency of transcription
in neuronal cells. The promoter assay showed that the construct
containing the -94delATTG promoter displayed significantly
Figure 2. Refined regional association plots. For each plot of the four clusters ((A) SLAMF1, (B) NFKB1, (C) DOCK4, and (D) RIPK4), the 2log10P
values for the trend test from Affymetrix SNP 6.0 Array in 522 cases and 806 controls are plotted as red diamond according to their genomic position
(NCBI Build 36.3). The SNPs with the strongest signal are represented as blue diamonds. The recombination rates (right y-axis) based on the Chinese
HapMap population is plotted as green lines to reflect the local LD structure around the SNPs. The dashed horizontal line indicates a P-value of 10
25.
doi:10.1371/journal.pone.0033598.g002
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type construct (2.5960.07) (P=0.003) (Figure 4).
Discussion
This study presented the data of the first GWAS on TRS in a
Han-Chinese population. Therefore, the use of genomic con-
trol did not substantially change the results of this GWAS
(Supplementary Table S5). The sample size is comparatively
smaller than in previous GWAS for schizophrenia due to the
smaller number of TRS patients available Since schizophrenia is
an etiologically heterogeneous disorder, narrowing schizophrenia
down to TRS may represent a more discrete and genetically
homogeneous group to identify genes involved in the etiology of
schizophrenia.
Among the genetic loci with suggestive significance identified by
this study, three regions with more than one significant SNP in
each region stood out after joint analysis. rs4699030 and rs230529
are located in the introns of NFKB1. This gene encodes for two
functional different proteins [35], one for the 105 kD (p105)
protein, and the other for a 50 kD (p50) protein. P105 contains
seven copies of ankyrin-like sequence in the carboxyl terminal
region which is similar to those in I-kappa B kinase (IkB),
therefore, p105 may also have functions similar to IkB. P105 could
associate with either c-Rel or RelA in the cytoplasm to inhibit Rel
protein-specific transcription [36,37]. P50 is one subunit of NF-
kappa B with repression activity. NF-kappa B is well distributed
and a highly conserved dimeric transcriptional factor which
regulates more than 200 genes [38]. Different dimeric combina-
tions of NF-kappa B are found in different tissues and respond
differently to regulate gene expressions. P50 assembles either with
other NF-kappa B subunits, such as RelA, RelB, c-Rel, or with
itself as a homodimer to repress NF-kappa B–dependent gene
transcriptions [39]. The heterodimer of p50 and RelA subunit is
the most abundant form of NF-kappa B [40].
Both rs10218843 and rs11265461 are located near SLAMF1
(also known as CD150), which is a signaling lymphocyte activation
molecule and a member of the CD2 family belonging to the
immunoglobulin superfamily of receptors. SLAM is a co-
stimulatory molecule involving T cell activation and also as a
receptor for measles virus [41], a bacterial sensor [42], and
responsible for the NKT lineage development [43].The activation
of SLAM has been shown to associate with numerous distinct
downstream activities, including augmenting T cell mediated
cytotoxicity through a sequence of signaling transduction,
including NF-kappa B activation, Stat1 phosphorylation and T-
bet induction [44]; increasing recruitment of protein kinase C
(PKC)-theta and the activation of NF-kappa B p50, both of which
are involved in enhancing T helper 2 cytokines production and
natural killer T cell development [45,46].
Table 3. Variants identified in NFKB1 by direct sequencing in 94 TRS cases and controls.
SNP Region Allele Genotype Effect
Risk
Allele RAF
F
difference
case (%) control (%) case control
rs28362491 P ATTG/- ins/ins:ins/-:-/- 24.4 : 46.7 : 28.9 31.7 : 47.8 : 20.5 del 0.522 0.444 0.078
rs11940017 P T.C TT:TC:CC 85.9 : 14.1 : 0 95.7 : 4.3 : 0 C 0.071 0.022 0.049
rs11944443 p A.G AA:AG:GG 85.9 : 14.1 : 0 95.7 : 4.3 : 0 G 0.071 0.022 0.049
rs41477752 I2 T.- TT:T/-:-/- 87.0 : 13.0 : 0 95.6 : 4.4 : 0 del 0.065 0.022 0.043
IVS2-60 A.GI 2 A .G AA:AG:GG 98.9 : 1.1 : 0 100.0 : 0 : 0 G 0.005 0 0.005
c.692 G.TE 8G .T GG:GT:TT 98.9 : 1.1 : 0 100.0 : 0 : 0 R231L T 0.005 0 0.005
rs4648049 I12 C.T CC:CT:TT 86.2 : 13.8 : 0 95.5 : 4.5 : 0 T 0.069 0.022 0.047
rs4648050 I12 T.C TT:TC:CC 25.5 : 36.2 : 38.3 27.0 : 49.4 : 23.6 C 0.564 0.483 0.081
IVS12+21 C.TI 1 2 C .T CC:CT:TT 98.9 : 1.1 : 0 100.0 : 0 : 0 T 0.005 0 0.005
rs1020760 I11 G.C GG:GC:CC 42.1 : 40.0 : 17.9 24.7 : 50.6 : 24.7 G 0.621 0.5 0.121
IVS11-56 T.CI 1 1 T .C TT:TC:CC 97.9 : 2.1 : 0 98.9 : 1.1 : 0 C 0.011 0.006 0.005
c.1116 G.AE 1 2G .A GG:GA:AA 98.9 : 1.1 : 0 100.0 : 0 : 0 S372S A 0.005 0 0.005
IVS13+196 T.GI 1 3 T .G TT:TG:GG 98.9 : 1.1 : 0 100.0 : 0 : 0 G 0.005 0 0.005
c.1601 G.AE 1 5G .A GG:GA:AA 98.9 : 1.1 : 0 100.0 : 0 : 0 R534H A 0.005 0 0.005
IVS15+12 C.GI 1 5 C .G CC:CG:GG 98.9 : 1.1 : 0 100.0 : 0 : 0 G 0.005 0 0.005
IVS15+40 G.AI 1 5 G .A GG:GA:AA 98.9 : 1.1 : 0 100.0 : 0 : 0 A 0.005 0 0.005
rs4648095 I17 T.C TT:TC:CC 81.1 : 18.9 : 0 93.6 : 9.6 : 0 C 0.095 0.032 0.063
rs4648110 I22 T.A TT:TA:AA 92.6 : 7.4 : 0 87.1 : 12.9 : 0 T 0.963 0.935 0.028
rs4648117 I22 C.T CC:CT:TT 80.6 : 19.4 : 0 94.3 : 5.7 : 0 T 0.097 0.028 0.069
IVS22-23 C.TI 2 2 C .T CC:CT:TT 97.8 : 2.2 : 0 100.0 : 0 : 0 T 0.011 0 0.011
rs3817685 I22 G.C GG:GC:CC 32.6 : 41.3 : 26.1 20.5 :52.3 : 27.3 G 0.533 0.466 0.067
rs35795162 I23 -/A -/-:-/A:AA 77.4 : 20.4 : 2.2 90.9 : 9.1 : 0 A 0.124 0.045 0.079
IVS23-44 G.AI 2 3 G .A GG:GA:AA 98.9 : 1.1 : 0 100.0 : 0 : 0 A 0.005 0 0.005
Risk allele means the allele with higher frequency in schizophrenia as compared with controls;
RAF: risk allele frequency.
P: promoter, I : intron.
doi:10.1371/journal.pone.0033598.t003
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RIPK4. The expression of RIPK4 is well distributed, including the
brain, and found to interact with PKC-delta [47]. This gene is
important in sensing cellular stress, such as infection, inflamma-
tion, cellular differentiation programs and DNA damage. It also
mediates downstream signaling, in particular the activation of NF-
kappa B and the induction of apoptosis [48].
The identification of NFKB1, RIPK4, and SLAMF1 in this study
suggests that the NF-kappa B pathway plays an important role in
the pathogenesis of TRS. NF-kappa is also found to be related
with schizophrenia since the genetic variants in RELA gene, which
encoded the protein RelA as one subunit of NF-kappa B, were
reported to be associated with schizophrenia and the patients
startle responses in a Japanese population [49]. NF-kappa B is a
Figure 3. LD plot of rs28362491 (-94delATTG). rs28362491 shows linkage disequilibrium with the Affymetrix SNPs. Both rs230529 and
rs4699030 have the lowest P value in this study.
doi:10.1371/journal.pone.0033598.g003
Figure 4. Reporter assay of rs28362491 (-94ins/delATTG) of NFKB1 in SH-SY5Y cells. pGL3 luciferase reporter contained either the -
94ATTGATTG (W) or the -94ATTG (D) allele at the promoter region of the NFKB1. Values represented the average of three experiments and the error
bars represented the standard deviation. pGL3-basic was used as control without any promoter sequence inserted. ** P,0.01.
doi:10.1371/journal.pone.0033598.g004
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many inflammatory factors, such as cytokines, chemokines, and
adhesion molecules [50]. Several studies have demonstrated that
schizophrenic patients’ cerebrospinal fluid and plasma had
abnormal levels of cytokines [51,52,53], the aberrations were
especially more pronounced in TRS [54,55,56]. Song et al. found
the elevated level of cytokine in first-episode schizophrenic
patients was associated with the activation of NF-kappa B [53].
Thus, these suggest abnormal inflammatory response could lead
to TRS. One common variant rs28362691 (-94ins/delATTG)
identified from resequencing NFKB1 was found to associate with
TRS. This SNP is located in 19 base pairs upstream of a
functional kB binding site [57]. The promoter assay showed that
the NFKB1 promoter with the -94delATTG allele had a lower
promoter activity in SH-SY5Y cells in comparison with the -
94insATTG allele. This implies that the -94delATTG allele may
result in lower expression of NFKB1.C h a n g e si nNFKB1
expression could alter the level of p105 and induce divergent
dimeric combinations of NF-kappa B, which might cause
disturbances in cytokine regulations, and lead to a failure of
antipsychotic treatment. However, the association between the
abnormal levels of cytokines and NF-kappa B in patients with
TRS remains to be established. Two novel non-synonymous
polymorphisms (R231L and R534H) were also identified from
resequencing. However, these polymorphisms have extremely low
frequency in the Han population and their effects on NFKB1
function remain to be elucidated.
Other genetic loci identified in association with TRS in this
study suggests genes involved in neuronal development (DOCK4
[58]). A recent study conducted in the Jewish population also
identified a SNP (rs2074127) in DOCK4 associated with
schizophrenia [59] however, this SNP is not in LD with the
DOCK4 SNPs reported in this study (Supplementary Figure S4).
Its role in the development of TRS remains to be elucidated.
We also compared our results with previous genetic studies
showing associations with TRS (such as variants in CYP3A4 [60],
CYP3A5 [60], DRD3 [60], HTR2A [61], HTR3A [62]), none of the
variants or their nearby SNPs had a P value lower than 10
25 in
this study. It implicated that these above genes involving in
metabolic enzymes and receptors of antipsychotics were not
associated with TRS. Furthermore, we also compared our data
with previous GWAS on schizophrenia. We examined the P values
of the loci previously reported to be associated with schizophrenia
in our data. We also checked the vicinity (200 kb) of the reported
loci in our data. Only rs1602565 on chromosome 11 showed
nominal association (P=3.17610
24) in this study (Supplementary
Table S6 and Supplementary Figure S5). These data suggested
that the genetic loci identified in this study were specifically
associated with TRS.
None of the loci identified in this study reached genome-wide
significance, this could due to tour sample size lack the statistical
power to detect common variants of susceptibility. However, we
focused on TRS within schizophrenia, which may represent a
more homogeneous group. An independent TRS group was also
not available for replication study. Future replication studies in
additional population of TRS are required.
In conclusion, we report the first GWAS on TRS in the Han
Chinese population. Our data suggest that the NF-kappa B
pathway may play an important role in the pathogenesis of TRS.
We have also provided the functional effect of the -94delATTG
allele showing the possible mechanism of NFKB1 in TRS. Further
studies are required to confirm the association of the risk alleles
identified in this study across different populations, to identify the
causative genetic variants, and to elucidate the underlying
molecular mechanisms, which may help to improve treatments
for refractory schizophrenia.
Materials and Methods
Subjects
This study was approved by the Institute Review Board of
Taipei Veterans General Hospital Kaohsiung, Kai-Suan Psychi-
atric Hospital, Jianan Mental Hospital, Bali Psychiatric Center,
Tsyr-Huey Mental Hospital, Yuli Veterans Hospital, National
Taiwan University Hospital and Academia Sinica. Written
informed consent was obtained from all the study participants.
A total of 522 unrelated patients with TRS, including 289 males
(55.4%) and 233 females (44.6%), were recruited from Yuli
Veterans Hospital, Taipei Veterans General Hospital, Kaohsiung
Kai-Suan Psychiatric Hospital, Tsyr-Huey Mental Hospital,
Jianan Mental Hospital, and Bali Psychiatric Center. DNA
samples from additional 273 TRS patients were obtained from
National Taiwan University Hospital and were used in joint
analysis. In addition, DNA samples from 1982 schizophrenic
patients were obtained from Yuli Veterans Hospital, Taipei
Veterans General Hospital, and National Health Research
Institutes. However, the responses to antipsychotic treatments for
1982 schizophrenic patients were not determined.
All patients were diagnosed according to the criteria of DSM-IV
for schizophrenia. TRS was defined using a modified Conley and
Kelly’s protocol [28]. Briefly, schizophrenic patients with the
following criteria were identified as TRS: No improvement in
clinical impression (defined as 3 or more in the global
improvement subscale of clinical global impression (CGI-I)) after
at least two six-week trials of antipsychotic therapy at a dose equal
to or higher than the equivalent daily dose of 600 mg of
chlorpromazine for typical antipsychotics, or for second-genera-
tion antipsychotics (risperidone: 6 mg/day; olanzapine: 20 mg/
day; quetiapine: 800 mg/day; ziprasidone: 160 mg/day; amisul-
pride: 800 mg/day; zotepine: 300 mg/day), as well as for patients
who were administered the last-line antipsychotic pharmacother-
apy, clozapine (50–300 mg/day). All patients with TRS showed
more than 5 years of persistent illness (defined as 4 or more in the
severity of illness subscale of clinical global impression (CGI-S)).
Informed consent was obtained from all participants. Only the
Han-Chinese population, which accounts for 98% of the
population in Taiwan, was recruited for this study.
The control (N=2806) was randomly selected from the Han-
Chinese Cell and Genome Bank in Taiwan described previously
[63], in which more than 3,300 controls were collected and
randomly selected through registry.
Genotyping and Quality Control
Genomic DNA was isolated from peripheral blood using
PUREGENE DNA purification system (Gentra Systems, Minne-
apolis, MN). Whole-genome scan was conducted using Affyme-
trixH Genome-wide Human SNP Array 6.0 (Affymetrix, Santa
Clara, CA, USA) on 522 TRS patients and 806 controls and
genotyping was performed by National Genotyping Center at
Academia Sinica. Genotype calling was determined by Affymetrix
Power Tool 1.10.2 (Affymetrix) using default parameters.
Quality control of genotype data was performed by examining
several summary statistics. First, individual’s gender was double
checked by calculating the ratio of loci with heterozygous calls on
the X chromosome; After calculating total successful call rate and
the minor allele frequency (MAF) of cases and controls for each
SNP, SNPs were excluded if one of the following conditions
applied: (1) only one allele appeared in both cases and controls; (2)
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than 5% and the total call rate was less than 99%; (4) significant
deviation from Hardy-Weinberg equilibrium in the control group
(P,10
24).
Population stratification
Detection of possible population stratification that might
influence association analysis was carried out using principal
component analysis (supplementary Methods S1, Supplementary
Table S7) with genotype data for 100,000 SNPs located at equally
spacing across the human genome. Plink (Supplementary
Methods S2) was performed to examine if the subjects were
related with each other. Variance inflation factor for genomic
control was estimated based on all qualified SNPs (Supplemen-
tary Methods S3).
Data Analysis
Genotyping data analysis was carried out by comparing the
frequencies of allele and genotype between cases and controls
using the following single-point methods: genotype, allele-type,
trend test (Cochran-Armitage test), dominant, and recessive
models. Empirical P-values were also obtained with 10
8 simula-
tions. SNPs with P-values less than a=10
28, a cut-off for the
multiple-comparison adjusted by Bonferroni correction, were
considered to be significantly associated with the traits. SNPs with
P-values between 10
28 and 10
25 were considered to have
suggestive significant association. Quantile–quantile (Q–Q) plots
were then used to examine P-value distributions (Supplementary
Figure S6).
Multi-point/haplotype analysis was performed using the
Haplotype Score Test [64] implemented in haplo.stat, a suite of
S-PLUS/R routines for the analysis of indirectly measured
haplotypes, for regions with more than two SNPs having genetic
evidences (P-value,10
25). Regions were tested with independent
10
6 simulations.
Validation and joint analysis
Autosomal SNPs with P-value,10
25 from GWAS in 522 TRS
cases and 806 controls were further validated using MALDI-TOF
mass spectrometry (SEQUENOM MassARRAY, Sequenom, San
Diego, CA, USA). The SNPs retained after cross-platform
validation were then genotyped in the additional 273 TRS cases.
Joint analysis was then carried out with all the 795 TRS cases and
806 control.
Direct Sequencing
Selected candidate genes were re-sequenced in a discovery
cohort consisted of 94 TRS patients and 94 controls. Exons,
200 bp of exon/intron junctions, and a 2–kb region covering the
promoter of the selected genes were sequenced using Applied
Biosystems 3730 (CA, USA). Contig assembly and SNP identifi-
cation were determined using Sequencher 4.5 Demo (Gene Codes
Cooperation, Ann Arbor, MI, USA). All PCR products were bi-
directionally sequenced.
Plasmid Construction for Luciferase Reporter Assay
To assay for the NFKB1 promoter activity, the NFKB1
promoter encompassing the -94ATTG polymorphism (from
21000 to 21) from patients with homozygous -94ATTGATTG
(W) or -94ATTG (D) were first cloned into the pGEM-T Easy
vector (Promega, Madison, WI, USA) with the forward primer: 59-
CCCGGGCCTGATTACTGATGTTTTAAAGCT-39 and the
reverse primer: 59-CTCGAGTTCCTGGCTGGAAATTCCCA-
CTGA-39. Both the W and D fragments were then released from
the pGEM-T Easy vector and subcloned into the upstream region
of the firefly luciferase gene of the pGL3-basic vector (Promega).
All constructs were subjected to sequencing to confirm the
orientation and integrity.
Transient Transfection and Luciferase Assay
A total of 1610
5 SH-SY5Y cells were seeded in each well of a
24-well plate and transfected with 450 ng of each reporter
construct along with 50 ng of pRL-TK vector (Promega)
containing the Renilla luciferase gene as an indicator for
normalization of transfection efficiency. Transfections were
performed by using FuGENE HD (Roche Applied Science,
Indianapolis, IN, USA) according to manufacturer’s instructions.
Cells were incubated for 24 hours and analyzed for luciferase
activity with the Dual-Luciferase Assay System (Promega). Firefly
luminescence was normalized to Renilla luminescence and
reported as relative luciferase activity. All experiments were
performed in triplicate and repeated at least three times.
Supporting Information
Figure S1 Principal component analysis (PCA) plot. The PCA
plot shows the first two principal components, estimated by
EIGENSTRAT (Price et al. Nature Genetics 38, 904–909 (2006)),
which was based on genotype data from 100,000 SNPs with
equally spacing across the human genome. No population
stratification between the 502 TRS cases (CA, marked as blue
circle) and 806 controls (CN, marked as pink cross) was detected
(P.0.05, and Fst statistics between populations ,0.001).
(DOCX)
Figure S2 LD blocks of the clusters showing suggestive
significant association. LD (r
2and D’) blocks of the clusters on
chromosome 1 (A), chromosome 4 (B), chromosome 7(C), and
chromosome 21 (D), the validated SNPs with P value lower than
10
25 are marked in blue.
(DOCX)
Figure S3 Refined regional association plots for the five
singleton SNPs with suggestive association. For each of the SNP
(A) rs461409, (B) rs123533497, (C) rs9314462, (D) rs9646303, and
(E) rs11673496, the 2log10P values for the trend test from
Affymetrix SNP 6.0 Array in 522 cases and 806 controls are
plotted as red diamond according to their genomic position (NCBI
Build 36.3). The SNPs with the strongest signal are represented as
blue diamonds. The recombination rates (right y- axis) based on
the Chinese HapMap population is plotted as green lines to reflect
the local LD structure around the significant SNPs. The dashed
horizontal line indicates a P-value of 10
25.
(DOCX)
Figure S4 LD blocks of the DOCK4 SNPs.
(DOCX)
Figure S5 Comparisons to previous GWAS. For each of the (A)
PTBP2,( B )PLXNA2, (C) ZNF804A,( D )FXR1, (E) MHC region/
SLC17A1/SLC17A3/BTN2A2/HIST1H2BJ/PRSS16/POM121L2/
ZNF184/PGBD1, (F) MHC region/NOTCH4/HLA-DQA1, (G)
RELN, (H) SMARCA2, (I) PLAA, (J) ANK3, (K) Intergenic region
on 11p14.1, (L) NRGN/I1 of HEPACAM, (M) Intergenic region on
16p13.2, (N) ACSM1,( O )TCF4,t h e2log10P-values from primary
scan are ploted as a function of genomic position (NCBI Build 36).
The reported SNPs in previous GWAS are denoted by blue
diamonds. Estimated recombination rates (right y axis) based on the
Chinese HapMap population is plotted to reflect the local linkage
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annotations and number of transcripts were taken from NCBI.
(DOC)
Figure S6 Quantile-quantile (QQ) plots. QQ plot is shown for
the trend test. P-values are based on the 694,436SNPs which
passed quality filters from 522 cases and 806 controls. The upper
and lower boundaries of the 95% confidence bands are
represented by the blue lines.
(DOCX)
Table S1 Quality control of the genotyping results. Breakdown
of the number (N) of SNPs and samples which passed the QC
filter.
(DOCX)
Table S2 Concordance rates for the 19 SNPs with significant
associations in the initial GWA analysis.
(DOCX)
Table S3 Multipoint/haplotype analysis of the clusters on
chromosome 1 (A), chromosome 4 (B), and chromosome 7(C).
(DOCX)
Table S4 Testing TRS association results with schizophrenia.
(DOCX)
Table S5 SNPs showing suggestive significant associations
adjusted using genomic control.
(DOCX)
Table S6 Previously reported loci and SNPs associated with
schizophrenia.
(DOCX)
Table S7 Adjustment of the top SNPs for drinking and inclusion
of 20 principal components as covariates in logistic regression.
(DOCX)
Methods S1 Principal component analysis using EIGEN-
STRAT.
(DOCX)
Methods S2 Analyses based on pair-wise identity-by-state (IBS)
distance using Plink.
(DOCX)
Methods S3 Genomic Control.
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